What Boltz does
Boltz (Boltz, PBC) is an AI-for-science company building open biomolecular foundation models and a hosted “Boltz Lab” platform that packages those models into production-oriented interfaces and agentic workflows for drug discovery. The company’s core model line includes Boltz-1 (open-source structure prediction for biomolecular complexes), Boltz-2 (joint structure and binding-affinity/co-folding), and BoltzGen (generative binder design across biomolecular modalities). Boltz’s product strategy is to keep frontier modeling research open while also commercializing the infrastructure, orchestration, and workflow layers required for scientists to reliably run designs, predictions, and iterative discovery loops at scale.
Boltz positions Boltz Lab as a way to reduce practical adoption bottlenecks—compute cost, scalable infrastructure, and collaboration-friendly interfaces—by providing optimized hosted inference plus the “agents” that help users execute end-to-end design workflows. The company also launched a Boltz API intended to be integration-ready for programmatic use and agent/tool calling, including first-party SDKs and integrations. Boltz’s commercial model (as described by the company) is usage-based pricing for hosted predictions/designs, with additional enterprise-style deployments and optional fine-tuning/customization for partners.
Strategically, Boltz’s recent period centers on (1) converting open models into enterprise-ready offerings, (2) expanding partnerships with major pharma for deployment of Boltz Lab and platform capabilities, and (3) broadening access of the Boltz API and models through integrations with AI tooling ecosystems (for example, Anthropic’s Claude Science).